Abstract
Prostate cancer remains a life-threatening disease of men. While early detection has been helpful to reduce the mortality rate, we currently do not have a desired therapy. In recent years, new strategies have been proposed to treat prostate cancers with poor prognosis by utilizing genetically modified bacteria, including Salmonella typhimurium that preferentially replicate within solid tumors (1000:1 and up to 10,000:1 compared to non-cancerous tissue) destroying cancer cells without causing septic shock that is typically associated with wild-type S. typhimurium infections. Furthermore, these bacteria have the potential to be utilized as drug delivery systems to more effectively target different subpopulations of prostate tumor cells. This chapter reviews progress in using genetically modified S. typhimurium for destruction of prostate tumors.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsReferences
Kazmierczak R, Choe E, Sinclair J, Eisenstark A (2015) Direct attachment of nanoparticle cargo to Salmonella typhimurium membranes designed for combination bacteriotherapy against tumors. Methods Mol Biol 1225:151–163. https://doi.org/10.1007/978-1-4939-1625-2_11
Lilleengen K (1948) Typing of Salmonella Typhimurium by means of bacteriophage. Acta Pathol Microbiol Scand.77 (supple.): 125
Bermudes D, Low KB, Pawelek J, Feng M, Belcourt M, Zheng LM, King I (2001) Tumour-selective Salmonella-based cancer therapy. Biotechnol Genet Eng Rev 18:219–233 Review
Demerec M (1958) Genetic structure of the Salmonella cromosome. X Int Congr Genet 1:55–62
Lederberg J (2000 May) The dawning of molecular genetics. Trends Microbiol 8(5):194–195
Eisenstark A (1971) Mutagenic and lethal effects of visible and near-ultraviolet light on bacterial cells. Adv Genet 16:167–198 Review
Ferron WL, Eisenstark A, Mackay D (1972 Sep 14) Distinction between far- and near-ultraviolet light killing of recombinationless (recA) Salmonella typhimurium. Biochim Biophys Acta 277(3):651–658
McCormick JP, Fischer JR, Pachlatko JP, Eisenstark A (1976 Feb 6) Characterization of a cell-lethal product from the photooxidation of tryptophan: hydrogen peroxide. Science 191(4226):468–469
Ananthaswamy HN, Eisenstark A (1977 Apr) Repair of hydrogen peroxide-induced single-strand breaks in Escherichia coli deoxyribonucleic acid. J Bacteriol 130(1):187–191
Ahmad SI, Eisenstark A (1979 May 4) Thymidine sensitivity of certain strains of Escherichia coli K12. Mol Gen Genet 172(2):229–231
Eisenstark A (1989) Bacterial genes involved in response to near-ultraviolet radiation. Adv Genet 26:99–147 Review
Arber W (2000 Jan) Genetic variation: molecular mechanisms and impact on microbial evolution. FEMS Microbiol Rev 24(1):1–7
Edwards K, Linetsky I, Hueser C, Eisenstark A (2001 May 30) Genetic variability among archival cultures of Salmonella typhimurium. FEMS Microbiol Lett 199(2):215–219
Faure D, Frederick R, Włoch D, Portier P, Blot M, Adams J (2004 Oct) Genomic changes arising in long-term stab cultures of Escherichia coli. J Bacteriol 186(19):6437–6442
Porwollik S, Wong RM, Helm RA, Edwards KK, Calcutt M, Eisenstark A, McClelland M (2004 Mar) DNA amplification and rearrangements in archival Salmonella enterica serovar typhimurium LT2 cultures. J Bacteriol 186(6):1678–1682
McClelland M, Sanderson KE, Spieth J, Clifton SW, Latreille P, Courtney L, Porwollik S, Ali J, Dante M, Du F, Hou S, Layman D, Leonard S, Nguyen C, Scott K, Holmes A, Grewal N, Mulvaney E, Ryan E, Sun H, Florea L, Miller W, Stoneking T, Nhan M, Waterston R, Wilson RK (2001 Oct 25) Complete genome sequence of Salmonella enterica serovar Typhimurium LT2. Nature 413(6858):852–856
Chakrabarty AM (2003 May) Microorganisms and cancer: quest for a therapy. J Bacteriol 185(9):2683–2686 Review
Loeffler M, Le’Negrate G, Krajewska M, Reed JC (2007 Jul 31) Attenuated Salmonella engineered to produce human cytokine LIGHT inhibit tumor growth. Proc Natl Acad Sci U S A 104(31):12879–12883
Fensterle J, Bergmann B, Yone CL, Hotz C, Meyer SR, Spreng S, Goebel W, Rapp UR, Gentschev I (2008 Feb) Cancer immunotherapy based on recombinant Salmonella enterica serovar typhimurium aroA strains secreting prostate-specific antigen and cholera to xin subunit B. Cancer Gene Ther 15(2):85–93
Forbes NS, Munn LL, Fukumura D, Jain RK (2003 Sep 1) Sparse initial entrapment of systemically injected Salmonella typhimurium leads to heterogeneous accumulation within tumors. Cancer Res 63(17):5188–5193
Low KB, Ittensohn M, Le T, Platt J, Sodi S, Amoss M, Ash O, Carmichael E, Chakraborty A, Fischer J, Lin SL, Luo X, Miller SI, Zheng L, King I, Pawelek JM, Bermudes D (1999) Lipid a mutant Salmonella with suppressed virulence and TNFα induction retain tumor targeting in vivo. Nat Biotechnol 17:37–41
Forbes NS (2010 Nov) Engineering the perfect (bacterial) cancer therapy. Nat Rev Cancer 10(11):785–794. https://doi.org/10.1038/nrc2934 Epub 2010 Oct 14. Review
Acknowledgements
Thanks to Jacki Kian Mehr for her professional skills in searching pertinent science literature, and in preparation of this chapter. I also appreciate my association with students and distinguished scientists worldwide for their insights into the role of genetics in cancer disease.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2018 Springer International Publishing AG, part of Springer Nature
About this chapter
Cite this chapter
Eisenstark, A. (2018). A Geneticist’s View of Prostate Cancer: Prostate Cancer Treatment Considerations. In: Schatten, H. (eds) Cell & Molecular Biology of Prostate Cancer. Advances in Experimental Medicine and Biology, vol 1095. Springer, Cham. https://doi.org/10.1007/978-3-319-95693-0_8
Download citation
DOI: https://doi.org/10.1007/978-3-319-95693-0_8
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-95692-3
Online ISBN: 978-3-319-95693-0
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)